Europe Changed the Rules for Biotech. The EU Biotech Act Perspective from MICS Central Laboratory

At a Glance: 

• Finance:  Mobilising €10 billion for Biotech companies in Europe 
• Innovation Framework: a unified EU push to lead the next wave of biotech innovation. 
• Regulatory: EU Biotech Act reduces trial approval times – cutting regulatory complexity to get innovations to patients sooner. 

The EU is pouring €10 billion into biotech and tearing down the regulatory barriers that slowed clinical trials for decades. At the same time, US sponsors rattled by FDA uncertainty are heading to Europe in growing numbers. The question isn’t whether the landscape is changing — it’s whether the infrastructure can keep up. 

The European Commission dropped a significant signal in December 2025. Quietly, amid the holiday noise, it published the proposed European Biotech Act — a sweeping regulatory and investment framework designed to position the EU as the world’s most attractive destination for life sciences by 2030. For those of us working in clinical research infrastructure every day, this is not background policy news. It is a direct indicator of where the next wave of trial activity is heading, and how competitive the environment around it will become. 

Here is how we read it as a Central Laboratory service provider that covers a major part of the clinical trial. 

What is the EU Biotech Act?
The European Commission proposed the Biotech Act on 16 December 2025, setting out a comprehensive EU-level framework aimed at making Europe a more competitive home for biotechnology and biomanufacturing. The core focus is on reducing regulatory complexity, driving innovation, scaling up EU-based manufacturing capacity, and mobilizing finance. The Act is currently moving through the legislative process, with final adoption expected in the last quarter of 2026 or the first quarter of 2027, and full application projected for 2027–2028.

Part One: A New Chapter for European Biotech — Faster, Better Funded, and Finally Taken Seriously 

For years, the honest conversation among European biotech founders went something like this: great science, painful path to market, and never enough capital to bridge the gap. The European Biotech Act is the Commission’s attempt to change that narrative — structurally, not just rhetorically. 

The proposal covers a broad set of measures, but two stand out for the clinical research ecosystem. 

Regulatory speed. The Act proposes streamlining existing frameworks — including the Clinical Trials Regulation (CTR), the Advanced Therapy Medicinal Products (ATMP) regulation, and the Substances of Human Origin (SoHO) regulation — to reduce time-to-market through accelerated clinical trial timelines and risk-proportionate requirements.¹

This is complemented by the FAST-EU pilot programme, a 23-member-state fast-track initiative for clinical trial authorisations that became operational in January 2026². In practice, what sponsors have historically experienced as a fragmented, slow, multi-country approval maze is being redesigned into a coordinated, harmonised pathway. For biotech companies that have been holding back European trial initiation precisely because of that complexity, this removes a major friction point. 

Access to finance. This is where the numbers become hard to ignore. On the same day the Biotech Act proposal was published, the European Commission and the European Investment Bank Group (EIB Group) jointly announced BioTechEU — an initiative to mobilise up to €10 billion in public-private investment into the biotech and life sciences sector across 2026 and 2027.³

The programme builds on the EIB Group’s existing €3.5 billion life sciences venture debt portfolio and the European Investment Fund’s approximately €800 million in annual venture capital investments into life sciences funds.⁴ The target areas are precisely where modern clinical trials are most complex: gene and cell therapies, personalised medicine, mRNA technologies, monoclonal antibodies, and AI-enabled diagnostics. 

“Under-investment is a major stumbling block for Europe’s biotech companies and a serious obstacle for our innovative start-ups.” — Olivér Várhelyi, EU Commissioner for Health & Animal Welfare⁵

What this means in practice is a cohort of European biotech companies — many of them early-stage, many focused on advanced therapies — who will, for the first time, have access to serious capital alongside a regulatory environment designed to help them move quickly into the clinic. A second Biotech Act, expected in autumn 2026 and focused on industrial and agri-food biotechnology, signals that this is a sustained policy direction, not a one-off initiative.⁶

For vendors operating in Central and Eastern Europe, this is a meaningful pipeline signal. More funded biotechs moving faster into clinical trials means more demand for the infrastructure that makes those trials work — specimen logistics, specialised assay development, biomarker testing, GCP-compliant workflows, and the kind of regulatory documentation expertise that sits at the intersection of science and compliance. 

Part Two: The American Biotech Wave — and the Very Real Question of Vendor Capacity 

There is a second current running alongside the European biotech growth story, and it is coming from across the Atlantic. 

The FDA’s regulatory environment has changed dramatically since 2022. Staffing reductions of over 3,500 positions, shifts in accelerated approval requirements, and growing uncertainty around timelines have forced a strategic rethink across the US biotech sector.⁷ Industry leaders are not waiting to see how it resolves. The CEO of Dare Bioscience, a San Diego-based women’s health company, stated plainly that her firm is “definitely looking at Europe first for certain products where the need is great and the US regulatory path has become more uncertain or slower.”

RA Capital Management, one of the major investors in early-stage biotech with approximately $9 billion in assets under management, confirmed that portfolio-wide discussions now routinely include whether to pursue European trial initiation ahead of the US. 

Consulting firm ProPharma Group reported a direct increase in inquiries from US biotech companies about preparing EMA filings and setting up European clinical trials — a shift explicitly attributed to FDA instability.⁸ The US share of global clinical trials has already declined from 21% in 2015 to 15% in 2024. Europe is actively positioning to capture that movement. France has committed €500 million under its Healthcare Innovation Plan 2030, and Germany’s National Pharma Strategy is accelerating clinical research through regulatory simplification and manufacturing incentives. The EU also launched its “Choose Europe” campaign with €500 million directed at recruiting international research talent.⁹

The result is a simultaneous convergence: European biotechs, newly funded and moving faster into trials under a more streamlined regulatory framework — and American biotechs looking for stable, high-quality trial infrastructure in a region where regulatory confidence is being actively rebuilt. 

This is where the vendor capacity question becomes acute. 

The global central laboratory services market is projected to grow from approximately $4 billion in 2026 to $6.7 billion by 2034 — a compound annual growth rate of 6.65%.¹⁰ Europe’s share of that growth is being driven by increasing biomarker adoption, precision medicine, immuno-oncology, and the rising complexity of cell and gene therapy programmes.¹¹ As demand rises, the competition for qualified, experienced clinical lab partners will intensify, especially for those who can handle PBMC processing, functional assays, companion diagnostics, GCP-compliant biorepository management, and multi-site coordination.  

American biotechs entering European trials for the first time will be navigating unfamiliar CRO landscapes, time zone logistics, and regulatory nuance. They will be competing for the same pool of experienced central lab partners as European sponsors. The difference is that European sponsors, particularly those in Central and Eastern Europe, often already have working relationships with regional providers who understand local regulatory environments, can support multi-country coordination, and offer the scientific depth to handle complex assay development without the overhead of a global mega-lab. 

For vendors like MICS, this creates a genuine window. The question is not whether demand will come — it will. The question is whether you are positioned to meet it: scientifically, operationally, and commercially. 

The Bottom Line 

The European Biotech Act, combined with the BioTechEU investment initiative and the accelerating reorientation of American biotech toward European trials, is not a distant forecast. It is a near-term shift in the clinical trial landscape that is already underway. European biotechs are going to move faster and with more capital behind them. American biotechs are going to arrive in increasing numbers, looking for local expertise and reliable infrastructure. 

At MICS, we see this as both a validation of the work we do and a call to scale what we do well — complex biomarker services, precision medicine support, GCP-compliant central laboratory operations, and site management capability across Central and Eastern Europe. The companies entering this space, whether they are starting in Warsaw or San Francisco, will need partners who can move with them. 

We are ready for that conversation. 

References

1. Crowell & Moring LLP. European Commission Proposes Biotech Act to Boost Health Biotechnology in the EU. December 2025. ↩︎
2.  Jones Day. The Proposed European Biotech Act, 100 Days On. April 2026.  ↩︎
3.  European Investment Bank. EIB and EC announce initiative to mobilise €10 billion for Europe’s biotech sector. December 2025. ↩︎
4. Euro Funding. EC and EIB Group Launch €10 Billion Initiative to Strengthen Europe’s Biotech Sector. December 2025. ↩︎
5. BioVox. European Biotech Act: New initiative to mobilize €10 billion investment. December 2025.  ↩︎
6.  European Parliament Think Tank. European Biotech Act — EU Legislation in Progress. April 2026.  ↩︎
7.   BioSpace. US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe. June 2025.  ↩︎
8.   Reuters / Investing.com. FDA upheaval pushes some biotech firms to plan early trials out of US. May 2025.  ↩︎
9.   eMarketer. Biotech and pharma consider moving early drug trials outside US. 2025.  ↩︎
10.  Fortune Business Insights. Central Lab Market Size, Share, And Growth Report, 2034.  ↩︎
11.   Future Market Insights. Central Lab Market Size, Growth Share & Trends to 2035. 2025.  ↩︎

FAQ about European Biotech ecosystem